EUCTR2013-000855-42-DE进行中（未招募）不适用
A Phase III, open-label, non-randomised, multi-centre, single dose study to assess immunogenicity and safety of Fluarix / Influsplit SSW 2013/2014 injected intramuscularly in adults (18 to 60 years of age) and in the elderly (over 60 years of age) - FLUARIX-072
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who the investigator believes can and will comply with the requirements of the protocol
- •A male or female aged 18 years or above at the time of vaccination.
- •Written informed consent obtained from the subject.
- •Healthy subjects or subjects with well-controlled chronic diseases as established by medical history and clinical examination before entering the study.
- •Female subjects of non-childbearing potential may be enrolled in the study
- •- Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause
- •Female subjects of childbearing potential may be enrolled in the study, if the subject:
- •-has practiced adequate contraception for 30 days prior to vaccination, and
- •-has a negative pregnancy test on the day of vaccination, and
- •-has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of vaccination
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •Participation in previous year’s Fluarix registration study (116663)
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs within the six months prior to vaccination. Inhaled and topical steroids are allowed.
- •Any administration of a long-acting immune-modifying drug within 6 months before study start, or planned administration during the study period.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the administration of the study vaccine or planned administration during the study period.
- •Administration of an influenza vaccine within the twelve months preceding the study vaccination.
- •Receipt of a vaccine other than the study vaccine within 30 days before study vaccination and/or plan to receive any vaccine other than the study vaccine during the entire study period.
- •Clinically or virologically confirmed influenza infection within the six months preceding the study vaccination.
- •Acute disease and/or fever at the time of enrolment.
- •- Fever is defined as temperature = 37.5°C/99.5°F on oral, axillary or tympanic setting, or = 38.0°C/100.4°F on rectal setting. The preferred route for recording temperature in this study will be axillary.
- •- Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.
- •Acute, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
- •Chronic underlying disease (such as cancer, chronic obstructive pulmonary disease under oxygen therapy, insulin-dependent diabetes mellitus), not stabilized or clinically serious.
- •History of chronic alcohol consumption and/or drug abuse.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •History of Guillain-Barré syndrome.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine including latex.
- •Anaphylaxis following the administration of vaccine(s).
- •Pregnant or lactating female.
- •Female planning to become pregnant or planning to discontinue contraceptive precautions.
- •Any condition which, in the opinion of the investigator, prevents the subject from participating in the study or would make intramuscular injection unsafe.
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity and safety study of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) Influsplit Tetra (Fluarix Tetra) (2013/2014 season) in adults 18 years of age and older.Immunization of healthy adults against influenzaMedDRA version: 14.1Level: LLTClassification code 10059430Term: Influenza immunizationSystem Organ Class: 100000004865EUCTR2013-001094-25-DEGlaxoSmithKline Biologicals
进行中（未招募）
不适用
Antibody persistence for GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (GSK-580299) administered in healthy adults and adolescents, 6.5 years after first vaccination in the primary study.Healthy volunteers [For active immunisation of females from 9 years of age onwards for the prevention of persistent infection, premalignant genital (cervical, vulvar and vaginal) lesions and cervical, vulvar and vaginal cancers (squamous-cell carcinoma and adenocarcinoma) caused by oncogenic Human Papillomaviruses (HPV)].MedDRA version: 16.1Level: LLTClassification code 10071147Term: Human papilloma virus immunizationSystem Organ Class: 100000004865MedDRA version: 16.1Level: LLTClassification code 10058580Term: Human papilloma virus serology testSystem Organ Class: 100000004848EUCTR2014-000060-17-DEGlaxoSmithKline Biologicals222
已完成
3 期
Clinical trial of an intranasal influenza vaccineCTRI/2019/04/018487Serum Institute of India Pvt Ltd400
已完成
3 期
A Phase III study to evaluate the immunogenicity, reactogenicity and safety of ROTAVAC 5CM compared with existing ROTAVAC® in healthy infants aged 6-8 weeksCTRI/2016/11/007481Bharat Biotech International Limited360
招募中
3 期
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)C349 Bronchus or lung, unspecifiedBronchus or lung, unspecifiedC349PER-062-22AstraZeneca AB31